Wegovy achieved a 30% higher prescription volume than initial forecasts within its first two weeks on the U.S. market, making it the fastest GLP-1 therapy launch in Novo Nordisk’s history and significantly boosting early sales momentum.

CEO Lars Fruergaard Jørgensen detailed plans to double injectable production capacity by Q4 2026, with capital allocated to expanding existing facilities and accelerating new manufacturing lines to meet sustained U.S. demand.